ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2010
High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 67 citations in OpenAlex.
- The Susceptibility Profiles of Human Peripheral Blood Cells toMicroorganisms · 2025Review
- Toxin-neutralizing Abs are associated with improved T cell function following recovery from Staphylococcus aureus infection.JCI insight · 2024Article
- In Reply.Deutsches Arzteblatt international · 2023Article
- Neutralization of the Staphylococcus aureus Panton-Valentine leukocidin by African and Caucasian sera.BMC microbiology · 2022Article
- Impaired T-Lymphocyte Responses During Childhood Staphylococcus aureus Infection.The Journal of infectious diseases · 2022Observational
- Tissue specificity drives protective immunity againstFrontiers in immunology · 2022Article
- Review
- Evasion of Immunological Memory byFrontiers in immunology · 2021Review
- Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia.The Journal of experimental medicine · 2020Article
- Retrospective Identification of a Broad IgG Repertoire Differentiating Patients WithFrontiers in immunology · 2019Article
- Article
- Human Memory B Cells TargetingmBio · 2018Article
- Catching the evader: Can monoclonal antibodies interfere with Staphylococcus aureus immune escape?Virulence · 2018Article
- Characterization of recombinant wild-type and nontoxigenic protein A from Staphylococcus pseudintermedius.Virulence · 2018Article
- Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors.Nature reviews. Microbiology · 2017Review
- Pyoderma outbreak among kindergarten families: Association with a Panton-Valentine leukocidin (PVL)-producing S. aureus strain.PloS one · 2017Article
- Review
- Investigational drugs to treat methicillin-resistant Staphylococcus aureus.Expert opinion on investigational drugs · 2016Review
- Typing of Panton-Valentine Leukocidin-Encoding Phages and lukSF-PV Gene Sequence Variation in Staphylococcus aureus from China.Frontiers in microbiology · 2016Article
- Proteomic Identification of saeRS-Dependent Targets Critical for Protective Humoral Immunity against Staphylococcus aureus Skin Infection.Infection and immunity · 2015Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCommunity-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) expressing Panton-Valentine leukocidin (PVL) causes severe skin and soft-tissue infection (SSTI), necrotizing pneumonia, and other invasive infections. The PVL toxin has been implicated as a virulence factor, and antibody to a component of this toxin is under investigation as a vaccine candidate. The role of PVL in pathogenesis remains controversial, and it is unknown whether human serum antibody to PVL modulates infection.
methodsWe determined antibody levels to PVL in serum samples from children aged 0-18 years presenting with polymerase chain reaction-confirmed, PVL-positive MRSA-associated SSTI (with or without prior MRSA infection or SSTI), PVL-positive MRSA invasive infection, and PVL-negative MRSA infection, as well as uninfected control subjects. We also measured antibody-mediated neutralization of PVL-induced lysis of human polymorphonuclear cells.
resultsAntibody to PVL was present in healthy children reaching adult levels by 4-6 years, with a nadir at 3-11 months likely due to loss of maternal antibody. Children with a primary PVL-positive MRSA infection had moderate levels of antibody to PVL that increased after infection. Children with prior MRSA infection or SSTI had high levels of antibody to PVL after the onset of PVL-positive MRSA infection. There was no increase in antibody to PVL in this population's serum samples after the onset of infection. Serum samples from children with PVL-positive MRSA-associated SSTIs, particularly those with prior MRSA infection or SSTI, and convalescent-phase serum samples from children with invasive PVL-positive MRSA infection potently inhibited PVL-induced lysis of polymorphonuclear cells.
conclusionsNeutralizing antibody to PVL does not protect children against primary or recurrent CA-MRSA-associated SSTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.